Skip to main content
. Author manuscript; available in PMC: 2015 Jan 26.
Published in final edited form as: Int J Gynecol Cancer. 2013 Nov;23(9):1612–1619. doi: 10.1097/01.IGC.0000436089.03581.6b

TABLE 5.

Association of PRBCT with OS within the PS strata

Propensity Score Strata
(Range; Sample Size*)
HR (95% CI) P
Strata 1 (0.084–0.349; 45 and 21) 1.08 (0.43–2.71) 0.87
Strata 2 (0.350–0.552; 40 and 27) 1.27 (0.60–2.70) 0.54
Strata 3 (0.553–0.780; 25 and 41) 0.82 (0.40–1.66) 0.57
Strata 4 (0.781–0.903; 10 and 57) 0.95 (0.43–2.09) 0.91
Strata 5 (0.904–0.964; 4 and 63) 0.41 (0.14–1.18) 0.10
Combined 0.90 (0.62–1.30) 0.58
*

Number of non-PRBCT and PRBCT patients, respectively.

The estimates were combined across the 5 strata using an inverse-variance weighted mean.